The July 23-24 PCAC Peptide Vote, Explained: What Happens to BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, and Epitalon

On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) will hold a public meeting at the White Oak campus in Silver Spring, Maryland to vote on whether seven peptides belong on the 503A bulks list. The list determines what licensed compounding pharmacies can prepare and dispense to patients on a prescription basis. The peptides under review: BPC-157, KPV, TB-500 (thymosin beta-4), and MOTS-c on Day 1; Emideltide (delta sleep-inducing peptide, DSIP), Semax, and Epitalon on Day 2.

The vote matters because most of these peptides came off the FDA's Category 2 'do not compound' list in April 2026. That move opened the door, but it did not finish the work. To stay open, each peptide needs an affirmative PCAC vote and then a final FDA decision to add it to the 503A bulks list. PCAC recommendations are advisory; the FDA can accept, modify, or reject them. The committee has historically followed the bulks-list standard closely on most reviews, but split decisions and partial approvals are common.

The stakes track to the compounding-pharmacy industry, the telehealth platforms (Hims & Hers, LifeMD) that bet on peptide expansion, and the gray-market vendors who would lose their pricing advantage if licensed channels open up. This piece walks through what each peptide does, what the evidence looks like, and what happens in either direction.

PCAC is an FDA advisory committee composed of independent scientific experts who review individual substances nominated for inclusion on the 503A or 503B bulks lists. The committee weighs four factors set out in regulation: the physical and chemical characterization of the substance, safety issues raised by its use in compounding, the available evidence of effectiveness for the proposed clinical use, and historical use of the substance in compounding, including the medical condition being treated and references in the medical literature.

The procedure: each substance gets a briefing document from FDA staff, then a presentation from the nominator (usually a compounding-pharmacy organization or a 503B outsourcing facility that wants the substance available), then a public-comment portion in which other parties can speak (oral-testimony registration closed June 30, written docket FDA-2025-N-6895 closes July 22), then committee discussion, then a recorded vote. A 'yes' vote is a recommendation that the FDA add the substance to the bulks list. A 'no' vote is a recommendation against. The FDA then makes the final administrative decision, often within weeks but sometimes much longer.

Key point: PCAC votes are not binding. The FDA can override either direction. In practice, the agency tends to follow committee recommendations on most reviews but has reversed PCAC several times in the past decade, usually toward stricter outcomes.

BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a sequence in body protection compound, a protein isolated from human gastric juice. Nominated use: ulcerative colitis and other gastrointestinal applications. The peptide has been used off-label since the 2000s in sports medicine and gray-market longevity protocols for muscle, tendon, and ligament injury recovery, gastric ulcer healing, and inflammatory bowel symptoms.

The evidence base: animal studies from Sven Sikiric's Croatian group at the University of Zagreb form the bulk of the published research, covering tendon-to-bone healing, vascular regeneration, and gastric mucosal protection in rodents. Human data is sparser. A small open-label pilot in inflammatory bowel disease showed promising symptom reduction. No randomized double-blind Phase 3 program exists. The molecule is not FDA-approved as a drug in any indication.

FDA's prior Category 2 designation cited limited US-standard clinical trial data and concerns about widespread marketing exceeding the evidence base. The April 23, 2026 Category 2 removal lifted the explicit prohibition but did not establish bulks-list eligibility. The July vote turns on whether the historical-use and animal-data record satisfy the four PCAC factors. A 'yes' vote opens 503A compounding for prescription preparations. A 'no' vote leaves BPC-157 in regulatory limbo: not banned, not approved, not eligible for compounding.

KPV is a tripeptide (lysine-proline-valine) that is the C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). Nominated use: anti-inflammatory applications including inflammatory bowel disease. The molecule has received attention in inflammatory dermatology and gastroenterology research and as an adjunct in BPC-157-style protocols.

The evidence base is thin. KPV has shown anti-inflammatory activity in mouse colitis models and in vitro work on melanocortin-1-receptor signaling. Human clinical data is limited to case reports and small open-label series. The compound has been used in compounding contexts for IBD and atopic dermatitis but does not have an FDA-approved drug indication. KPV is one of the lower-profile substances under review and likely to draw the least public attention. The PCAC vote will turn primarily on whether the historical-use record and safety profile satisfy the bulks-list criteria, since the effectiveness evidence is the weakest of the seven.

TB-500 is the brand/research name commonly applied to a synthetic active fragment of thymosin beta-4, a 43-amino-acid actin-sequestering peptide naturally found in human serum. The compound under review is the synthetic fragment, not full-length thymosin beta-4 (which has been studied separately under the name TB4-001 by RegeneRx Biopharmaceuticals). Nominated use: tissue repair, including tendon and ligament injury recovery, wound healing, and cardiac tissue repair.

The research base: RegeneRx ran multiple Phase 2 trials of full-length thymosin beta-4 in dry eye, neurotrophic keratitis, and pressure ulcers in the 2010s with mixed results. The synthetic fragment marketed as TB-500 has been used in veterinary sports medicine (it is on the WADA prohibited list for horse racing) and in gray-market human protocols, but no completed Phase 3 human RCT for any indication exists. The peptide has a strong proposed mechanism (actin sequestration accelerates cell migration in repair) but the clinical evidence in humans for the specific TB-500 sequence is limited primarily to case reports and small uncontrolled series.

A PCAC vote in favor would primarily reflect the safety profile and the long historical compounding use rather than effectiveness data. A vote against would track the limited human RCT record.

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded by the 12S ribosomal RNA gene in mitochondrial DNA. Nominated use: obesity and osteoporosis. The molecule is unique on this list in that it has a genuinely mechanistic story rooted in human metabolic biology and an active academic research program at USC and other institutions.

The evidence base: published preclinical work shows MOTS-c modulates AMP-activated protein kinase (AMPK) signaling, improves insulin sensitivity in mice, and protects against age-related metabolic decline. The Cohen lab at USC has been the leading academic group. Human trial data is limited: a Phase 1/2 trial in HIV-associated lipodystrophy ran in the late 2010s with limited published outcomes; broader Phase 2 work in obesity and insulin resistance is in early stages. Like TB-500 and BPC-157, MOTS-c has been used extensively in gray-market longevity protocols, but no FDA-approved drug indication exists.

The interesting question for the PCAC vote: MOTS-c has a stronger mechanistic story than BPC-157 or KPV but a similarly thin clinical evidence base. The committee may weigh the academic research program (USC, ongoing) more favorably even if formal human RCTs are missing.

Emideltide is the modern naming convention for delta sleep-inducing peptide (DSIP), a 9-amino-acid neuropeptide first isolated by Schoenenberger and Monnier from rabbit cerebral venous blood in 1977. Nominated use: sleep disorders. The peptide is among the longest-studied compounds on this list, with research stretching back nearly 50 years across European (especially Swiss and Russian) institutions.

The evidence base: several small placebo-controlled trials in the 1980s and 1990s evaluated DSIP for insomnia, chronic pain, and opioid withdrawal, with mixed results. The cleanest published data is in opioid-detoxification adjunct use; the sleep-disorder data is suggestive but underpowered. Russian medical practice has used DSIP variants for several decades. The peptide is not FDA-approved as a drug. A PCAC vote will turn primarily on whether the 50-year compounding history and the suggestive (if underpowered) sleep-disorder data meet the bulks-list standard. The molecule has a stronger historical-use claim than most of the others on the list.

Semax is a heptapeptide synthesized from the ACTH(4-10) fragment with a tetrapeptide tail. Developed in the Soviet Union in the 1980s and approved in Russia in 2011 for ischemic stroke recovery and cognitive disorders. Nominated US compounding use: cognitive function. The molecule is dosed intranasally for cognitive applications and has a substantial Russian-language research literature.

The evidence base: Russian-published clinical trials in ischemic stroke recovery, transient ischemic attack, and pediatric cognitive applications report positive effects, but the trials are typically not blinded, are small, and use measurement methods that don't always translate to Western neurology endpoints. Western RCT evidence is thin. The peptide has been on the Russian Vital and Essential Drugs list, which gives it a substantial prescribing history but does not establish FDA-grade evidence.

The PCAC vote here is interesting because the historical-use record is strong (Russian medical practice, decades of prescriber experience) but the evidence-of-effectiveness factor is weak by Western RCT standards. The committee's reading of how to weigh non-US-approved drug practice will set precedent.

Epitalon (also Epithalon) is a tetrapeptide (alanine-glutamate-aspartate-glycine) developed by Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology in the 1980s as a synthetic version of an extract isolated from the pineal gland. Nominated use: 'healthy aging,' specifically telomerase activation and circadian regulation.

The evidence base: Khavinson's group published small clinical studies in the 2000s claiming telomerase activation, melatonin normalization, and reduced age-related mortality in elderly patients. The studies are small, often uncontrolled, and have not been replicated by independent Western groups. The molecule is one of the most aggressively marketed longevity peptides in the gray market and on social media. No FDA-approved drug indication exists. The Russian-language research literature is the principal evidence base.

Epitalon is likely to draw the strongest skeptical scrutiny at PCAC because the gap between the marketing claims (telomerase activation, lifespan extension) and the published evidence (small uncontrolled Russian studies) is the widest on the list. The committee may vote on a procedural basis to require additional safety data even if it accepts the historical-use claim.

If PCAC recommends 'yes' on one or more peptides and the FDA accepts, the affirmative action is to add the substance to the 503A bulks list. The practical consequences:

Licensed compounding pharmacies (state-board-licensed, USP-795 and USP-797 compliant, often PCAB-accredited) can prepare prescription preparations using the substance as a bulk active pharmaceutical ingredient sourced from an FDA-registered API supplier. Patient access happens through a prescribing physician on a per-patient basis (not bulk manufacturing).

Telehealth platforms with in-house or partner pharmacies (Hims & Hers, LifeMD) can offer the peptide as a covered product line. The Hims business case explicitly assumes affirmative PCAC outcomes drive the 2027+ growth thesis (FirstWave Fund's $10-19 billion peptide-revenue forecast for Hims by 2030 sits on this assumption).

Gray-market and research-chemical vendors lose their relative pricing position because licensed channels become available. The April 2026 Utah federal indictment of an osteopathic physician for selling misbranded Chinese peptides illustrates the enforcement track that runs alongside reclassification.

The affirmative outcome does not mean FDA drug approval. The molecules remain investigational from a labeling standpoint; the compounded preparations cannot be marketed with disease claims; and the underlying clinical evidence does not change.

If PCAC recommends 'no' and the FDA accepts, the substance does not go on the 503A bulks list. The practical consequences:

The peptide stays in a regulatory limbo: not on Category 2 (so the explicit ban is lifted), not on the 503A list (so licensed compounding is not authorized), and not FDA-approved as a drug (so prescription drug marketing is not authorized). Pharmacies that compound the substance face enforcement risk; physicians who prescribe it lose the formal supply channel.

Gray-market and research-chemical channels continue to dominate access. Demand does not disappear; supply just routes through unregulated paths.

Individual physicians can still file expanded-access (single-patient IND) applications for specific patients, but those are administrative individual cases rather than a population-scale supply channel.

The Hims & Hers growth thesis takes a real hit. Analyst price targets ($39 from Barclays on June 17) bake in some peptide upside; a 'no' vote across the board would force a reassessment.

A mixed outcome (some 'yes,' some 'no') is the most likely scenario. The committee has historically split votes on multi-substance reviews. MOTS-c and BPC-157 may track favorably on the mechanistic and historical-use factors while Epitalon and KPV may struggle on the effectiveness factor.

PCAC will record votes on July 23 and 24. The committee's recommendations go to FDA staff for final consideration. Historically the agency has acted on bulks-list recommendations within 4 to 12 months of the meeting, sometimes faster on substances with clean unanimous votes. Several things to watch in the post-vote period:

The FDA's written rationale. The agency publishes its accept-or-reject decision in the Federal Register with a public-comment opportunity. The rationale explains how the four factors were weighed and which evidence was considered controlling.

The BALANCE Model January 2027 launch. The Medicare GLP-1 Bridge ($50/month, starts July 1, 2026) bridges to the BALANCE Model. The model is GLP-1-specific and does not directly affect the non-GLP-1 peptides under PCAC review, but the broader Medicare obesity-coverage architecture sets the policy context.

Individual state-board actions. Some state boards (Alabama May 2026, Ohio February 2026) have added prescribing restrictions on peptides regardless of the federal bulks-list status. A federal 'yes' vote does not preempt state-level restrictions.

Enforcement signaling. The FDA may issue warning letters to compounding pharmacies that prepared non-listed peptides during the Category 2 period, even after the explicit prohibition was lifted in April 2026. The enforcement track and the bulks-list track run on separate timelines.

The shortest path to a clear answer for patients: watch the FDA Federal Register filing in the 30 to 90 days following July 24. That filing will tell you definitively which of the seven peptides moved to legal 503A compounding status and which did not.